Larimar Therapeutics
LRMR
42 hedge funds and large institutions have $20.2M invested in Larimar Therapeutics in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 12 closing their positions.
0.28% more ownership
Funds ownership: 5.57% → 5.85% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 49 → 42 (-7)
27% less capital invested
Capital invested by funds: $27.7M → $20.2M (-$7.46M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.08M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$596K |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$423K |
| 4 |
O
OrbiMed
New York
|
+$313K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$188K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.01M |
| 2 |
Renaissance Technologies
New York
|
-$247K |
| 3 |
Two Sigma Investments
New York
|
-$241K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$147K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$94K |
LRMR Hedge Fund Activity: Q1 2020 in Review
42 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2020, worth a combined $20.2M — down 27% from $27.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LRMR and 6 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 8 added.
The largest buyer was Sphera Funds Management, adding an estimated $3.08M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $2.01M sold.
- 42 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2020, down from 49 in Q4 2019.
- Funds reported $20.2M of Larimar Therapeutics stock for Q1 2020, down 27% quarter-over-quarter.
- 6 funds opened new Larimar Therapeutics positions in Q1 2020 and 12 closed out, a net change of -6 holders.
- The largest Larimar Therapeutics buyer in Q1 2020 was Sphera Funds Management, an estimated $3.08M added.
- The largest Larimar Therapeutics seller in Q1 2020 was Farallon Capital Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2020.